Want to see KEQU full AI Analyst Report?
Top Page
Kewaunee Scientific
(NASDAQ:KEQU)
Select Model
Select Model
Rating:62Neutral
Price Target:
$40.00
â–²(5.88% Upside)
Action:Reiterated
Date:08/27/26
The score is primarily constrained by weakened financial quality—especially 2026 TTM operating/free cash flow at zero and increased leverage—despite improved profitability and margins versus prior years. Technicals are modestly supportive with positive momentum and price holding above key averages, and valuation appears reasonable with a low-teens P/E, but these are not enough to fully offset the cash-flow and balance-sheet risks.
Positive Factors
Improved profitability and gross margins
The sustained margin improvement indicates better pricing, product mix, and execution. If maintained, stronger gross profitability can support operating earnings and provide greater resilience across laboratory construction and renovation cycles.
Negative Factors
Operating and free cash flow at zero
A lack of cash conversion weakens earnings quality and limits internally funded investment, debt reduction, and working-capital flexibility. The contrast with positive profitability raises concern that project timing or balance-sheet needs may persistently absorb cash.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved profitability and gross margins
The sustained margin improvement indicates better pricing, product mix, and execution. If maintained, stronger gross profitability can support operating earnings and provide greater resilience across laboratory construction and renovation cycles.
Read all positive factors
Kewaunee Scientific Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where Kewaunee Scientific is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where Kewaunee Scientific is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyKewaunee Scientific (KEQU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$106.11M
Dividend Yield4.89%
Average Volume (3M)2.78K
Price to Earnings (P/E)11.0
Beta (1Y)0.89
Revenue Growth17.27%
EPS Growth-15.71%
CountryUS
Employees1,231
SectorConsumer Cyclical
Sector Strength84
IndustryFurnishings, Fixtures & Appliances
Share Statistics
EPS (TTM)3.35
Shares Outstanding2,868,511
10 Day Avg. Volume2,684
30 Day Avg. Volume2,780
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.42
Price to Sales (P/S)0.38
P/FCF Ratio7.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kewaunee Scientific Business Overview & Revenue Model
Company Description
Kewaunee Scientific Corporation, established in 1906 and based in Statesville, North Carolina, specializes in providing custom furniture and infrastructure systems for scientific, medical, and technical settings. The company manages its operations...
How the Company Makes Money
Kewaunee Scientific primarily makes money by selling laboratory furniture and ventilation-related lab products, along with associated project and installation services, to customers building new labs or renovating existing facilities. Revenue is g...
Kewaunee Scientific Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 282.00M | 240.47M | 203.75M | 219.49M | 168.87M |
| Gross Profit | 80.44M | 68.86M | 52.05M | 35.59M | 24.22M |
| EBITDA | 23.88M | 22.76M | 18.04M | 8.16M | 916.00K |
| Net Income | 9.62M | 11.40M | 18.75M | 1.36M | -6.00M |
Balance Sheet | |||||
| Total Assets | 178.31M | 194.65M | 134.77M | 118.90M | 118.77M |
| Cash, Cash Equivalents and Short-Term Investments | 11.62M | 14.94M | 23.27M | 8.08M | 4.43M |
| Total Debt | 30.18M | 50.16M | 11.00M | 12.92M | 67.56M |
| Total Liabilities | 101.50M | 128.41M | 78.56M | 80.41M | 82.59M |
| Stockholders Equity | 74.72M | 64.46M | 54.76M | 37.41M | 35.69M |
Cash Flow | |||||
| Free Cash Flow | 14.70M | 12.62M | 15.19M | -7.94M | -9.79M |
| Operating Cash Flow | 18.63M | 14.78M | 19.56M | -3.79M | -7.88M |
| Investing Cash Flow | -3.94M | -30.90M | -4.37M | -4.15M | -1.91M |
| Financing Cash Flow | -19.33M | 7.41M | -3.01M | 14.93M | 11.03M |
Kewaunee Scientific Technical Analysis
Neutral
37.78
Price Trends
36.67
Positive
37.16
Negative
37.69
Negative
Market Momentum
0.14
Positive
50.32
Neutral
16.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KEQU, the sentiment is Neutral. The current price of 37.78 is above the 20-day moving average (MA) of 36.89, above the 50-day MA of 36.67, and above the 200-day MA of 37.69, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 50.32 is Neutral, neither overbought nor oversold. The STOCH value of 16.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KEQU.
Kewaunee Scientific Risk Analysis
Kewaunee Scientific disclosed 28 risk factors in its most recent earnings report. Kewaunee Scientific reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kewaunee Scientific Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $336.18M | 12.35 | 19.78% | 1.03% | 4.10% | 73.26% | |
69 Neutral | $566.80M | 14.42 | 8.40% | 21.39% | -5.72% | -22.50% | |
64 Neutral | $165.89M | 30.29 | 3.32% | 4.18% | 1.96% | 122.75% | |
64 Neutral | $140.93M | -6.10 | -13.04% | 4.38% | -25.67% | -96.05% | |
62 Neutral | $106.11M | 11.04 | 13.63% | 4.89% | 17.27% | -15.71% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
53 Neutral | $102.56M | -42.31 | -2.32% | 1.53% | -18.97% | -118.61% |
* Consumer Cyclical Sector Average
KEQU
Kewaunee Scientific
36.99
-17.81
-32.50%
BSET
Bassett Furniture
19.16
3.14
19.58%
ETD
Ethan Allen
22.49
-1.72
-7.10%
FLXS
Flexsteel
82.16
33.97
70.48%
HOFT
Hooker Furniture
13.12
2.84
27.60%
VIRC
Virco Manufacturing
6.52
-1.53
-18.98%
Kewaunee Scientific Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Kewaunee Scientific Shareholders Endorse Board and Governance
Positive
Aug 27, 2026
On August 26, 2026, Kewaunee Scientific Corporation held its Annual Meeting of Shareholders, where investors re-elected Class I directors Thomas D. Hull III, David S. Rhind, and John D. Russell to three-year terms, signaling continuity in the comp...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Kewaunee Scientific Highlights Strong Fiscal 2026 Growth Strategy
Positive
Aug 26, 2026
Kewaunee Scientific has posted an investor presentation and script for its August 26, 2026 virtual annual shareholder meeting, detailing multi-year growth, segment performance and the strategic integration of its Lab Products Group platform. The c...
Business Operations and StrategyFinancial Disclosures
Kewaunee Scientific to Release Q1 FY2027 Results
Neutral
Aug 25, 2026
On August 25, 2026, Kewaunee Scientific Corporation announced it would release its first quarter fiscal year 2027 financial results on September 9, 2026, after the close of trading.The planned disclosure underscores the company’s ongoing com...
Financial Disclosures
Kewaunee Scientific Schedules Fiscal 2026 Earnings Release
Neutral
Jun 10, 2026
Kewaunee Scientific Corporation, a long-established global supplier of laboratory, healthcare, and technical furniture, offers a broad range of products from casework and fume hoods to biological safety cabinets and work surfaces. With manufacturi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.